Vitiligo is a hypomelanotic autoimmune skin disease arising from a breakdown in immunological self-tolerance, which leads to aberrant immune responses against melanocytes.
Introduction
Vitiligo is a hypomelanotic autoimmune skin disease resulting from loss of functional melanocytes from the skin with a prevalence of 1-2% [1] . The disease can affect individuals of any race or sex and manifests before the age of 20 years in approximately half of all cases [1] .
Although vitiligo might be considered a minor disorder, the psychological effects of the disease are frequently considerable. Individuals with the disease may experience feelings of stress, embarrassment, self-consciousness and low self-esteem particularly when in professional or social situations [2] . This is particularly the case in people with darkly pigmented skin where the appearance of depigmented patches is very prominent and also where vitiligo develops on visible areas of the body such as the face, hands and arms [3] . To date, no universally effective and safe therapy for the disease exists. Many treatment options have been developed, but challenges persist as not all patients respond to the available therapies, relapse is common and complete repigmentation is rarely accomplished [4] .
The exact aetiology and detailed pathogenesis of vitiligo is not fully understood, but autoimmunity has been strongly implicated in the development of the disease [5] . The current -of-thehe convergence theory which suggests that several factors can act synergistically or independently to induce the disappearance of melanocytes from the skin [5] . In the elicitation phase of vitiligo, triggers including physical trauma to the skin, emotional stresses, and imbalances of endogenous neural factors, metabolites or hormones lead to oxidative stress within melanocytes which then respond by actively secreting heat-shock protein 70 and chaperoned melanocyte antigens [6] . During the immune activation stage, -presenting dendritic cells with the subsequent activation and recruitment of anti-melanocyte autoreactive cytotoxic T lymphocytes to the skin [7] (Fig. 1 ).
The importance of autoimmunity in the aetiology of vitiligo is backed by recently identified susceptibility genes which include those involved in regulating the immune response such as PTPN22, CTLA-4, FOXP1, and those encoding certain major histocompatibility complex antigen specificities [8] . In addition, several studies have identified a pivotal role for cytotoxic T cells in inducing melanocyte-specific destruction in vitiligo [7] , including the findings that CD8 + T cells isolated from vitiligo skin are cytotoxic to melanocytes, recognise melanocyte-specific autoantigens [7] , and induce autologous melanocyte apoptosis through IL-6 and IL-13 [9] (Fig.   1 ). In addition, there is a global expansion and widespread activation of the CD8 + T cell population in vitiligo patients [10] [11] [12] . So far, however, the exact mechanisms underlying the induction and activation of autoreactive CD8 + T cells and the loss of tolerance to melanocyte autoantigens in vitiligo are not clear, but as with other autoimmune disorders, it seems likely that this loss of tolerance to self must involve some defect in regulatory T cell (Tregs) function [10, 11, 13] .
Regulatory T cells are a subset of CD4 + lymphocytes that play a key role in maintaining peripheral tolerance in vivo through the active suppression of self-reactive T cell activation and expansion ( Fig. 1) This review will address recent findings concerning the role of Tregs in the pathogenesis of vitiligo. In addition, as antigen-specific Tregs are a potential route for the reinstatement of immune tolerance, new strategies which expand or induce de novo generation of Tregs and which are currently being investigated as therapies for other autoimmune diseases, will be discussed and will highlight the opportunities for Treg-based therapeutics in vitiligo.
Regulatory T cells in vitiligo
An initial indication that a defect in Treg cell function could contribute to the progressive depigmentation of the skin came from studies of murine melanoma where the depletion of 
Cytotoxic T lymphocyte antigen-4
Cytotoxic T lymphocyte antigen-4 (CTLA-4 or CD152) is a T cell surface molecule involved in regulation of T cell activation and plays a critical role in the maintenance of tolerance to selfantigens [42] . Moreover, knock-out mouse models have shown that CTLA-4 plays a key role in
Treg cell function and maintaining peripheral tolerance [43] [44] [45] . It is therefore not surprising that the abnormal function of the molecule has been implicated in the aetiology of several autoimmune diseases including vitiligo [46] [47] [48] . Indeed, both soluble (sCTLA-4) and full-length (flCTLA-4) CTLA-4 mRNA have been found at decreased levels in vitiligo patients, which could perturb the normal suppressive capacity of Tregs [46] . Vitiligo has also been associated with the presence of the CT GG (rs3087243) allelic variation of CTLA-4, this in turn being correlated with the reduction in CTLA-4 mRNA levels [46] .
Transforming growth factor-
Transforming growth factor-is important for imposing a regulatory phenotype on the A number of studies indicate that decreased TGFin vitiligo patients, and this could have a deleterious effect upon Treg cell function in these individuals [58] [59] [60] . In addition, serum concentrations of TGF-have been shown to be decreased in cases of active but not stable vitiligo, indicating that lower levels of the cytokine are positively correlated with disease progression [61] . Furthermore, the reduced levels of TGFsecreted by vitiligo patient Tregs are negatively correlated with the percentage of depigmented body area [62] . Interestingly, three single nucleotide polymorphisms of the TGFreceptor 2 gene (TGFBR2) (rs2005061, rs3773645, rs3773649) are associated with vitiligo susceptibility [63] , although it is not yet clear how these allelic variants influence the expression of TGF-.
Interleukin-10
Tregs induced by IL-10 contribute to Treg cell-mediated immunosuppression principally by producing IL-10 [64] [65] . Several pieces of evidence suggest a role for IL-10 in the pathogenesis of vitiligo. For example, decreased IL-10 levels have been demonstrated in cases of active but not stable vitiligo, suggesting that IL-10 might play an important role in disease progression [61] . In addition, our recent study has also suggested a decrease in IL-10 mRNA expression in vitiligo patients as compared to healthy controls (Dwivedi et al., unpublished results). Interestingly, increased IL-10 expression in vitiligo lesions has been shown to occur after topical tacrolimus treatment suggesting that the inhibition of melanocyte destruction is triggered by unchecked Th1 pathways in vitiligo [66] . Furthermore, genetic susceptibility to vitiligo has been reported to be associated with polymorphisms in the IL-10 gene in Saudi patients: the GG genotype at -1082 and the CC genotype at positions -592 and +819 were significantly more prevalent in vitiligo patients compared to controls [67] . However, it has not been established whether these promoter polymorphisms play a role in the altered IL-10 expression.
Animal models also indicate a role for IL-10 in vitiligo development. Studies of Smyth line chickens, an animal model for human autoimmune vitiligo, have demonstrated that elevated leukocyte infiltration in early and active vitiligo is accompanied by increased levels of cytokine expression, especially in interferon (IFN)-IL-10, and IL-21 [68] . Recently, in a mouse model of spontaneous melanoma, Treg cell-depletion and IL-10 neutralisation led to an increased occurrence of vitiligo which correlated with a decreased incidence of melanoma metastases [69] . Further investigations indicated that reduced expression of chemoattractant CCL22 within vitiligo patient skin is primarily responsible for impaired migration of Tregs into the tissue.
Cell-homing capacity

Regulatory T cells as therapeutic targets for vitiligo
The studies discussed above certainly render Treg cells as crucial immune regulators involved in vitiligo pathogenesis. Approaches to correct defects in numbers or functions of
Tregs may, therefore, be valuable in the treatment of autoimmune vitiligo.
Adoptive transfer therapy using regulatory T cells
Systemic treatments for autoimmune disorders directed at augmenting Treg cell activities in vivo may be associated with significant off-target effects, including a generalised immunosuppression that may compromise beneficial immune responses. Therefore, the adoptive transfer of in vitro-generated, antigen-specific iTregs is a potential therapy option for autoimmune disorders. Treg cells can indeed be expanded ex vivo with allogeneic B cells [70] and these express very high levels of FoxP3, maintain an anergic phenotype, and are potent suppressors capable of inhibiting activated T cell responses [70] . 
Use of probiotics for the induction of regulatory T cells
The administration of microbes or microbial metabolites for the prevention and treatment of aberrant immune response is gaining importance [87] . The term probiotic refers hich, when consumed in adequate amounts, confer a health effect [88] . The protective effects associated with these microbes are mediated by multiple mechanisms involving T cells, dendritic cells and epithelial cells. An increasingly recognised feature of immunoregulatory microbes is their ability to induce Treg cells [87] . It has been demonstrated that oral consumption of Bifidobacterium infantis 35624 is associated with enhanced IL-10 secretion and FoxP3 expression in human peripheral blood [89] . Overall, these findings indicate the therapeutic potential of oral administration of a combination of probiotics in the management of autoimmune diseases and they therefore have similar potential for the treatment of vitiligo. However, further animal as well as human studies are required to provide evidence for the possible use of probiotics in the therapy of skin depigmentation.
Other approaches used for the induction of regulatory T cells
A number of other approaches have been used for the induction of Treg cells, and these are summarised in this section. However, their full potential for treatment of autoimmune diseases including vitiligo remains to be explored.
Acidic polysaccharide of Panax ginseng
An acidic polysaccharide of Panax ginseng (APG) has multiple immunomodulatory effects through instigating the production of a variety of anti-inflammatory cytokines. Studies have shown that APG significantly ameliorates the progression of experimental autoimmune encephalomyelitis by inhibiting the proliferation of autoreactive T cells and promoting the generation of immunosuppressive Tregs through the activation of FoxP3 [97] . Recently, Ahmad et al. [98] showed that 5-aminoisoquinolinone treatment significantly up-regulated the number of Tregs, I B (NF-B inhibitor)-levels and mRNA expression of anti-inflammatory mediators, thereby reducing the arthritis scores in adjuvant-induced arthritis in mice.
Interleukin-5
Tran et al. [99] have shown that IL-5 is able to promote the induction of antigen-specific treatment [99] . Overall, the study suggested IL-5 therapy may be able to induce antigen-specific tolerance in autoimmune disease. Tregs in patients with type 1 diabetes [101] . In addition, allogenic stem cell transplantation was found to lead to full recovery from primary biliary cirrhosis where peripheral blood lymphocytes were completely deficient in the -subunit of the IL-2R (CD25) [102] .
Interleukin-2 and interleukin-2 receptor
Self antigen-derived peptides
Recent experimental work and preclinical studies have provided proof-of-concept for the induction of self-tolerance through the modulation of Tregs using self antigen-derived peptides which then promote suppression of hyperactive CD4 + T cells and the production of pathogenic autoantibodies [103] . This study suggested that alloantigen-specific vasoactive intestinal peptide-generated Tregs could be a valuable tool in therapeutic interventions to promote immunotolerance toward allogeneic grafts [104] . Analogous approaches could be developed for specific autoimmune diseases.
Anti-CD3 monoclonal antibody
The stimulation of T cell receptors with modified anti-CD3 monoclonal antibody has been applied to expand the CD8 + T cell population and induce CD8 + CD25 + Tregs in patients with type 1 diabetes [105] . The study highlighted the clinical efficacy of this method of treatment of an autoimmune disease which prevented the loss of insulin production over the first two years of the disease and reduced insulin usage.
Granulocyte-macrophage colony-stimulating factor
Sheng et al. [106] showed that the treatment with granulocyte-macrophage colonystimulating factor (GM-CSF) resulted in amelioration of experimental autoimmune myasthenia gravis, accompanied by a down-regulation of autoreactive T cell and pathogenic autoantibody responses, a mobilisation of dendritic cells with a tolerogenic phenotype, and an expansion of
Tregs that potently suppressed acetylcholine receptor-stimulated T cell proliferation in vitro.
The study provided evidence that the mobilization of antigen-specific Tregs in vivo using pharmacologic agents, like GM-CSF, can modulate ongoing immune responses against specific antigens capable of suppressing antibody-mediated autoimmunity.
B cell-mediated pathways
It is known that B cells participate in the immune system through antibody production.
Interestingly, Walters et al. [107] have recently reported that intrathymic B cells are involved in production of CD4 + FoxP3 + nTregs. Such information offers the possibility of using the B cellmediated pathway of nTreg cell generation in the Treg cell-mediated therapy of vitiligo.
Regulatory T cell/Th17 cell balance
The transcription factors STAT5 and STAT3 are known to control the differentiation of
Tregs and Th17 cells, respectively. Inhibiting STAT3 using siRNA has been shown to significantly increase the proportion of Treg cells and decrease the proportion of Th17 cells in the CD4 + T cell population from the peripheral blood and synovial fluid of patients with rheumatoid arthritis [108, 109] . The inhibition of STAT5 has the counter effects [108, 109] . In the same study, no change was found to be induced by STAT3 or STAT5 siRNA in the production of Th1 versus Th2 signature cytokines [108] , suggesting that these signalling pathways could provide novel target molecules for the control of Treg cells in the treatment of autoimmune disease, including vitiligo.
Enhanced killing activity of regulatory T cells
An alternative approach for using Treg cells therapeutically has been to enforce their proapoptotic activity by decorating them with Fas-L protein [110] . The Fas-L-labelled Tregs showed sustained inhibitory activity in relation to T cell proliferation in vitro and were also found to be efficient in preventing the progression in mouse models of autoimmune insulitis and chronic colitis [110] . Though promising, the efficacy of such an approach has yet to be studied in relation to the treatment of human autoimmune disorders including vitiligo.
Conclusions
The exact role of Tregs in the development of vitiligo has yet to be established unequivocally. Particularly, there are still conflicts in the data regarding Treg cell numbers and function in vitiligo patients. Future studies will reveal detailed mechanisms by which Treg cells are involved in maintaining tolerance against pigment cell-specific antigens, such that alternative therapeutic approaches which could manipulate Treg cells and specifically dampen B and T cell autoreactivity towards melanocytes without affecting general immunity may be a way forward.
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Take-home messages
 Vitiligo patients present with defects in the function and numbers of regulatory T cells which may lead to increased levels of CD8 + T cells with anti-melanocyte activity.
 Antigen-specific adoptive transfer of Tregs and other approaches for inducing Treg cells seem to be efficient in ameliorating autoimmune disease, and thus may also serve as therapeutics for vitiligo.
 Further studies for determing the exact role of Tregs in the pathogenesis of vitiligo are required to pave the way for improved treatments. Quantitative and functional status of Treg cells in vitiligo patients.
Treg cell numbers
Decreased in blood and increased in skin Table 2 .
Genetic polymorphisms of FOXP3 studied in vitiligo. 
